Who Paid My Doc
James Klinger
Pulmonary Disease Riverside, RI Medical Doctor
NPI 1639123854 CMS profile 209472
375 Wampanoag Trl, Suite 302B, Riverside, RI 02915
General payments
$2,633
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$2,727,342
Through program year 2025, James Klinger of Riverside, RI is reported in the CMS Open Payments database as having received $2,633 across 18 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,727,342 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 56th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $233 | 3 | |
| 2024 | General | $2,039 | 6 | |
| 2022 | General | $117 | 2 | |
| 2021 | General | $179 | 6 | |
| 2019 | General | $64 | 1 |
Beside peers
- James Klinger
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to James Klinger were reported at $233. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | James Klinger | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $64 | $377 | $109–$1,340 | $163 |
| 2020 | $0 | $230 | $56–$907 | $114 |
| 2021 | $179 | $269 | $68–$1,072 | $132 |
| 2022 | $117 | $390 | $100–$1,457 | $149 |
| 2023 | $0 | $419 | $114–$1,659 | $160 |
| 2024 | $2,039 | $476 | $123–$1,818 | $164 |
| 2025 | $233 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
597
Drug cost
$786,093
Branded share of claims
48.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Adempas Riociguat | Brand | 17 | $219,389 | |
| Opsumit Macitentan | Brand | 13 | $166,974 | |
| Tracleer Bosentan | Brand | 11 | $140,743 | |
| Ambrisentan | Generic | 38 | $78,493 | |
| Tadalafil | Generic | 40 | $44,055 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 52 | $33,268 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 55 | $29,764 | |
| Eliquis Apixaban | Brand | 32 | $23,139 | |
| Sildenafil Citrate | Generic | 62 | $17,366 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 14 | $10,142 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$44,553
Medicare patients
194
Services billed
484
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 56% | |
| COPD | 56% | |
| Arthritis | 48% | |
| Ischemic heart disease | 47% | |
| Chronic kidney disease | 43% | |
| Diabetes | 40% | |
| Atrial fibrillation | 39% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Rhode Island
Michael Stanchina
Pulmonary Disease · East Greenwich, RI
William Corrao
Pulmonary Disease · Warwick, RI
Corey Ventetuolo
Pulmonary Disease · Riverside, RI
John Ladetto
Pulmonary Disease · Riverside, RI
Christopher Mullin
Pulmonary Disease · Providence, RI
Raffi Calikyan
Pulmonary Disease · Bristol, RI
Related records
Pulmonary Disease in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.